41 min
Talk evidence covid-19 update - talking risk, remdesivir, and relevant research The BMJ Podcast
-
- Medicine
In this talk evidence covid-19 update, we’re taking on risk - how do you figure out your individual risk of dying from the disease? Try QCovid, but remember that it’s figuring out your risk back in April.
When it comes to talking about risk, very few people actually engage with the number, so Alex Freeman from the Winton Centre for Risk and Evidence Communication at the University of Cambridge joins us to describe their research into more effective ways of presenting it.
Huseyin Naci, from the London School of Economics, returns to the podcast to talk to us about the problems of pulling all the trial data together, and where covid-19 has made people work together most effectively in tackling that issue.
Reading list;
Living risk prediction algorithm (QCOVID) for risk of hospital admission and mortality from coronavirus 19 in adults
https://www.bmj.com/content/371/bmj.m3731
Repurposed antiviral drugs for COVID-19 –interim WHO SOLIDARITY trial results
https://www.medrxiv.org/content/10.1101/2020.10.15.20209817v1
Producing and using timely comparative evidence on drugs: lessons from clinical trials for covid-19
https://www.bmj.com/content/371/bmj.m3869.full
In this talk evidence covid-19 update, we’re taking on risk - how do you figure out your individual risk of dying from the disease? Try QCovid, but remember that it’s figuring out your risk back in April.
When it comes to talking about risk, very few people actually engage with the number, so Alex Freeman from the Winton Centre for Risk and Evidence Communication at the University of Cambridge joins us to describe their research into more effective ways of presenting it.
Huseyin Naci, from the London School of Economics, returns to the podcast to talk to us about the problems of pulling all the trial data together, and where covid-19 has made people work together most effectively in tackling that issue.
Reading list;
Living risk prediction algorithm (QCOVID) for risk of hospital admission and mortality from coronavirus 19 in adults
https://www.bmj.com/content/371/bmj.m3731
Repurposed antiviral drugs for COVID-19 –interim WHO SOLIDARITY trial results
https://www.medrxiv.org/content/10.1101/2020.10.15.20209817v1
Producing and using timely comparative evidence on drugs: lessons from clinical trials for covid-19
https://www.bmj.com/content/371/bmj.m3869.full
41 min